Adarza BioSystems is a biotechnology company pioneering a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.
Adarza leading develops and manufactures label-free biosensor assays and instruments servicing life science research, drug development and, in-vitro diagnostics customers.
Adarza BioSystems was founded in 2008 by Rand Henke and Benjamin Miller. The company is headquartered in Maryland Heights, Missouri.
Adarza delivers industry leading precision, accuracy, and robustness enabling highly multiplexed protein detection with high sensitivity and specificity.
Adarza’s platform is capable of rapidly identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing. Its technology offers key performance benefits in speed, ease of use, large screening arrays, and custom assays as well as industry-standard expectations for sensitivity, sample size, and dynamic range.
Adarza products address broad quantitative analyte detection applications, including cancer biomarkers, drug and vaccine development, allergy, immunology, and infectious diseases research.
Adarza BioSystems is backed by 3×5 Partners, Lightchain Capital, BioGenerator, RiverVest Venture Partners, Cultivation Capital and others. TThe company raised $25M in a Series D round on Feb 04, 2020. This brings Adarza's total funding to $53.3M to date.